• Full year 2025 DAYBUE net sales of US$391 million, up 12% YoY
• Q4 2025 DAYBUE net sales of US$110 million, up 13% vs PCP and 8% QoQ
• Neuren's full year 2025 royalty income A$65 million, up 15% YoY

Neuren Pharmaceuticals (ASX: NEU) reported highlights from the Q4 and full year 2025 earnings announcement and conference call of its partner Acadia Pharmaceuticals (Nasdaq: ACAD). Acadia announced full year 2025 DAYBUE net sales of US$391 million, an increase of 12% on 2024 and within its prior guidance range of US$385-400 million. Q4 2025 net sales of US$110 million represented 13% growth compared with Q4 2024 and 8% growth compared with Q3 2025, marking a new quarterly record since the launch of DAYBUE in April 2023. The number of unique patients receiving a DAYBUE shipment continued to grow, reaching a new record of 1,070 in Q4 2025. Neuren's full year 2025 royalty income from DAYBUE was A$65 million, an increase of 15% on 2024 and within Neuren's prior guidance. Acadia has provided guidance for full year 2026 DAYBUE net sales in the range of US$460 million to US$490 million, which would result in Neuren's royalty income of approximately A$70 million to A$77 million.

Acadia provided full year 2026 DAYBUE net sales guidance of US$460 - 490 million, implying royalty income to Neuren of A$70 million to A$77 million.

In Europe, Acadia currently plans to request re-examination of the CHMP opinion following its formal adoption at the end of February 2026, with the CHMP opinion on the re-examination likely at the end of Q2 2026. In Japan, the Phase 3 clinical trial of trofinetide is ongoing with top-line results expected between Q4 2026 and Q1 2027 to facilitate a marketing application in 2027.